A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation.
Principal investigator: Juha Lievonen
HUS Helsinki University Hospital, Comprehensive Cancer Center
